These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

571 related items for PubMed ID: 28458514

  • 1. Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.
    Lian TY, Jiang X, Jing ZC.
    Drug Des Devel Ther; 2017; 11():1195-1207. PubMed ID: 28458514
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension.
    Ghofrani HA, Humbert M, Langleben D, Schermuly R, Stasch JP, Wilkins MR, Klinger JR.
    Chest; 2017 Feb; 151(2):468-480. PubMed ID: 27263466
    [Abstract] [Full Text] [Related]

  • 5. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Bishop BM.
    Am J Health Syst Pharm; 2014 Nov 01; 71(21):1839-44. PubMed ID: 25320133
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Soluble guanylate cyclase stimulators in pulmonary hypertension.
    Stasch JP, Evgenov OV.
    Handb Exp Pharmacol; 2013 Nov 01; 218():279-313. PubMed ID: 24092345
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Riociguat: a review of its use in patients with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension.
    Garnock-Jones KP.
    Drugs; 2014 Nov 01; 74(17):2065-78. PubMed ID: 25352393
    [Abstract] [Full Text] [Related]

  • 12. Riociguat for the treatment of pulmonary hypertension.
    Meis T, Behr J.
    Expert Opin Pharmacother; 2014 Nov 01; 15(16):2419-27. PubMed ID: 25260791
    [Abstract] [Full Text] [Related]

  • 13. Riociguat for the treatment of pulmonary hypertension.
    Hambly N, Granton J.
    Expert Rev Respir Med; 2015 Nov 01; 9(6):679-95. PubMed ID: 26599488
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study.
    Halank M, Hoeper MM, Ghofrani HA, Meyer FJ, Stähler G, Behr J, Ewert R, Fletcher M, Colorado P, Nikkho S, Grimminger F.
    Respir Med; 2017 Jul 01; 128():50-56. PubMed ID: 28610669
    [Abstract] [Full Text] [Related]

  • 18. Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat.
    Frey R, Becker C, Saleh S, Unger S, van der Mey D, Mück W.
    Clin Pharmacokinet; 2018 Jun 01; 57(6):647-661. PubMed ID: 29086344
    [Abstract] [Full Text] [Related]

  • 19. [The achievements of the modern specific therapy of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: focus on the stimulator of soluble guanylate cyclase riociguat].
    Gratsianskaya SE, Valieva ZS, Martynyuk TV.
    Ter Arkh; 2020 Oct 14; 92(9):77-84. PubMed ID: 33346435
    [Abstract] [Full Text] [Related]

  • 20. Treatment of pulmonary hypertension with riociguat: a review of current evidence and future perspectives.
    Boutou AK, Pitsiou G.
    Expert Opin Pharmacother; 2020 Jul 14; 21(10):1145-1155. PubMed ID: 32089012
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.